When the XPRIZE Foundation named the 11 finalists for the Nokia Sensing XCHALLENGE, I had a chance to interview a team in which I see great potentials. Here is my short talk with the French team behind ARCHIMEJ TECHNOLOGY, a start-up led by co-founder Francisco Vega, developing technology focused on making blood analysis available remotely at an affordable price.
1) Can you tell me more details about the technology behind your solution?
I’m afraid I’m not going to be able to say much on that topic; everything is confidential for the moment. What I can tell you is that we have completely reimagined the linear process by which the measurement/analysis is performed today, to transform it into a complex multi-factor analysis, which paradoxically simplifies the entire process of testing.
There is 3 important parts in our technology:
– The technology that holds and conditions the sample for the measurement (sample = a drop of blood from finger-stick);
– The technology that performs the measurement (called Spectroscopy 2.0®);
– The technology that analyses the information measured and interprets it in test results easy to understand by the user.
2) How can it be compared to Theranos which has similar goals?
What Theranos does is amazing! ..I mean, being able to perform hundreds (even maybe thousands) of tests with only a tiny volume of blood is already a huge step from anything existing.
What we do is taking this concept and trying to push it even further. We will not perform hundreds of tests (or at least not for now, maybe in the future), but for the moment we focus on those the most used, the most important ones and in making them available to people directly in their homes.
Our solution, Beta-Bioled, is a comprehensive and integrated platform that allows doctors and patients to get a blood-chemistry panel (10 to 20 tests) from 1 drop of blood, anywhere, in real time, for less than 2 dollars.
This idea of democratization of blood analysis, this.. new way for everybody to have access to medical relevant diagnostic is possible because of 3 factors: the mobility (or portability), the simplicity of use and the cost. If you miss one of those 3 factors the impact will not be the same, you will still be targeting a specific group of people or an elite..
3) How does your innovation contribute to the process of breaking down the “ivory tower” of medicine and making even blood analysis accessible to patients?
Imagine that you could monitor your heart, your liver, your kidneys, your lipids profile.. as if you were in a hospital but from the comfort of your home, with a fast and simple process and paying less in a month that what you pay for a coffee every morning.
It will be a huge step in the democratization of healthcare. Instead of going to check your health status when you are feeling unwell, you could anticipate and prevent. It would change the whole healthcare paradigm: less urgencies, and aggressive medication but smoother preventive treatments or lifestyle adjustments.
..Well this is exactly what we do; playing our part in the switch from industrial medicine that treats the symptoms to a personal preventing medicine.
Of course this transition is a process, and that’s why we are prepared to address each step of the transition, in order to speed it up.
– For existing medical facilities, our solution fits the needs of both patients and physician by reducing clinic overload, streamlining the process of performing a blood panel and receiving results instantly and more importantly, onsite.
– For emergency services and NGOs, it becomes an on-the-ground, easy to use ally to quickly make decisions and prioritize treatments.
– For medically underserved regions, either low medical infrastructure or low density of population, it becomes a bridge able to obtain and connect meaningful data to distant medical experts.
– Finally, for the elderly, and more generally for the chronic patients, who intend for more than 20% of all patients in the wealthy country, it brings them the so wanted autonomy and comfort.